Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...

Cantor Fitzgerald initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage issued an overweight rating on the stock.

Guggenheim initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $ ...

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...

Michael Saylor buys 20,356 BTC for $1.99 billion, funding purchases with stock sales as shares drop 16%. Bitcoin's slump adds more risk.

Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...

On Tuesday, Cantor Fitzgerald began coverage of Metsera Inc (NASDAQ:MTSR) with an Overweight rating, highlighting the biotech company's potential in the obesity drug market. The firm's analyst ...